Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$3.32
-$0.04(-1.25%)
At close: 4:00 PM EDT
$3.32
-$0.04(-1.25%)
Day’s Range― - ―
52-Week Range$2.32 - $13.42
Previous Close$3.26
Volume20.73K
Average Volume (3M)32.23K
Market Cap
$7.02M
Enterprise Value-$3.23
Total Cash (Recent Filing)$8.54M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,142,546
10 Day Avg. Volume23,674
30 Day Avg. Volume32,231
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)88.41
Price to Sales (P/S)1211.03
P/FCF Ratio-54.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.00Price Target Upside140.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline And Regulatory PathwaysMultiple late-stage programs and established FDA and EMA pathways provide several potential routes to commercialization. These designations may reduce regulatory uncertainty and improve partnering prospects, although approval remains dependent on successful trials.
A3AR Platform And Partnering PotentialClinical safety experience across a broad patient base supports reuse of the A3AR platform across oncology, liver and inflammatory indications. Existing licensing income also demonstrates commercial interest and may help validate future partnering potential.
Expanding Intellectual Property ProtectionAdditional international patent protection can extend exclusivity around Namodenoson in important oncology indications. Broader protection may strengthen negotiating leverage with partners and support future commercialization if clinical and regulatory objectives are achieved.
Bears Say
Declining Revenue And Persistent LossesShrinking revenue and worsening net losses show that the company has not yet established a self-sustaining commercial model. Continued operating deficits could constrain development capacity and increase reliance on financing or licensing proceeds.
Ongoing Cash Burn And Funding DependencePersistent negative operating and free cash flow means clinical development is not funded internally. Continued cash consumption raises the need for external capital, partnerships or other funding, creating execution and potential dilution risks over the medium term.
Volatile Equity Base And Weak Shareholder ReturnsAlthough leverage is low, declining and volatile equity reflects the cumulative effect of ongoing losses and cash burn. This weak capital foundation may limit financial flexibility and make future funding more consequential for existing shareholders.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.32 and its highest was $13.42 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $7.02M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Apr 01, 2027 which is in 210 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Aug 27, 2026. The company reported -$0.33 earnings per share for the quarter.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.33 in its last earnings report. Following the earnings report the stock price went up 1.506%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$8.00
▲(140.96% Upside)